Zevra Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Zevra Therapeutics has a total shareholder equity of $61.9M and total debt of $42.8M, which brings its debt-to-equity ratio to 69.1%. Its total assets and total liabilities are $172.3M and $110.5M respectively.
Key information
69.1%
Debt to equity ratio
US$42.77m
Debt
Interest coverage ratio | n/a |
Cash | US$67.74m |
Equity | US$61.86m |
Total liabilities | US$110.46m |
Total assets | US$172.33m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1GDA's short term assets ($86.9M) exceed its short term liabilities ($73.7M).
Long Term Liabilities: 1GDA's short term assets ($86.9M) exceed its long term liabilities ($36.7M).
Debt to Equity History and Analysis
Debt Level: 1GDA has more cash than its total debt.
Reducing Debt: 1GDA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1GDA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1GDA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.